Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

National Jewish Health And Ceragenix Announce Compound Shows Promise For Treating Potentially Lethal Viral Infections
Ceragenix Pharmaceuticals, Inc.("Ceragenix") (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, announced that researchers at National Jewish Health, led by Dr. Donald Y. Leung and Dr. Michael Howell, in collaboration with Dr. Paul B. Savage of Brigham Young University, have demonstrated in a series of in vitro experiments and preclinical animal testing that an investigational drug compound known as CSA-13 shows promise as a potential therapy to treat viral infections from the vaccinia virus. The research appears ahead of print in an advanced online publication of the Journal of Investigate Dermatology, the official journal of the Society for Investigative Dermatology. This work was funded by the National Institute of Allergy and Infectious Diseases Atopic Dermatitis Vaccinia Network.
generic viagra online
Cancer's Distinctive Pattern Of Gene Expression Could Aid Early Screening And Prevention
Distinctive patterns of genes turned off - or left on - in healthy versus cancerous cells could enable early screening for many common cancers and maybe help avoid them, Medical College of Georgia scientists say.
News of the day
Slumping Economy Hurts Health System, But Stimulus Provides Some Relief
The receding economy has dragged down Michigan"s health care system, "offering a preview of how a lingering recession could corrode Americans" hospitals, savings and health," the Wall Street Journal reports.
Health Insurance

Online Reporting System For Swine Flu Antiviral Side Effects

Suspected side effects to swine flu antiviral medicines can now be reported to the Medicines and Healthcare products Regulatory Agency (MHRA) via a new dedicated webpage (http://www.mhra.gov.uk/swineflu). The online system is based on the highly successful Yellow Card Scheme and is designed to make completing a report quick and easy for the public as well as healthcare professionals. This will assist the MHRA in efficiently monitoring the safety of the swine flu antiviral medicines, Tamiflu and Relenza, as their use increases during the swine flu pandemic. MHRA Director of Vigilance and Risk Management of Medicines, Dr June Raine, said Tamiflu and Relenza are acceptably safe and most people will not suffer any side effects. "Like all medicines, the MHRA keeps the safety of these continually under review and we are keen to let people know there is a new way to tell us of any side effect suspicions. "If someone thinks they may have had a side effect to their medication, they should see their healthcare professional first to check they are okay. They should then report it to the MHRA via the "Swine Flu ADR Portal". "If they are unable to access the Internet, their healthcare provider can send a report on their behalf. "By providing this information, not only are the MHRA able to gain better insights into the safety of medicines, but people can directly contribute to effective medicines regulation." Notes 1. The UK has stockpiled the antiviral medicines Tamiflu and Relenza for management of the swine flu pandemic. 2. The existing Yellow Card Scheme will remain in operation during this time for reporting suspected ADRs to all other medicines. 3. The MHRA has received 20 suspected ADR reports to Tamiflu and no suspected ADR reports to Relenza since the start of the swine flu outbreak. No new risks have been identified. MHRA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009